State of New Jersey Common Pension Fund D’s Protalix BioTherapeutics PLX Stock Holding History

State of New Jersey Common Pension Fund D’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-24,000	Closed	-$876K	–	930
2014 Q2	$876K	Hold	24,000	–	–	﹤0.01%	850
2014 Q1	$1.1M	Hold	24,000	–	–	0.03%	57
2013 Q4	$934K	Hold	24,000	–	–	0.03%	45
2013 Q3	$1.09M	Hold	24,000	–	–	0.03%	46
2013 Q2	$1.18M	Buy	+24,000	New	+$1.27M	0.04%	45

Other funds holding PLX

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

MTWSIF

Mivtachim The Workers Social Insurance Fund Tel Aviv, Israel $789M AUM 73.25% 1-Year Est. Return

BlackRock Group London, United Kingdom $210B AUM 15.5% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

State of New Jersey Common Pension Fund D's PLX Position: Q3 2014 in Review

State of New Jersey Common Pension Fund D sold out of Protalix BioTherapeutics (PLX) in Q3 2014, closing a stake of 24,000 shares — an estimated $876K sold.

State of New Jersey Common Pension Fund D first reported a position in PLX in Q2 2013 and held it in 5 quarters. The position peaked at $1.18M in Q2 2013. 43 funds tracked by Wall St. Rank hold PLX as of Q3 2014.

State of New Jersey Common Pension Fund D reported no remaining Protalix BioTherapeutics position as of Q3 2014 after selling out during the quarter.
State of New Jersey Common Pension Fund D sold 24,000 Protalix BioTherapeutics shares in Q3 2014, an estimated $876K.
State of New Jersey Common Pension Fund D first reported a position in Protalix BioTherapeutics in Q2 2013 and held it in 5 quarters.
State of New Jersey Common Pension Fund D's Protalix BioTherapeutics position peaked at $1.18M in Q2 2013.
43 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q3 2014.

Based on State of New Jersey Common Pension Fund D's 13F filing for Q3 2014, filed 3 Nov 2014.